Mineralys Therapeutics, Inc. (MLYS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$28.21-0.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Mineralys is advancing the commercial launch of lorundrostat, a key product. The company aims to finalize an agreement to end future royalty payments, improving capital allocation. Recent positive earnings beats show some operational progress. Debt issuances provide funding for growth.
Mineralys remains loss-making with negative EPS expected through 2027. The commercial launch of lorundrostat is not yet proven. Earnings estimates have been revised down recently. Capital allocation issues and debt raise risks.
The market currently prices in continued losses with EPS around -$0.56 next quarter and -$2.24 for FY26. Our view is cautious given the lack of revenue and ongoing losses, expecting challenges in commercial execution and capital structure.
Breaks if: EPS loss worsens or remains flat through FY27
Breaks if: failure to advance commercial launch milestones through FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a turnaround investment thesis with a focus on the healthcare sector. The current state reflects a mix of stable management and weak recent performance, leading to a cautious outlook.
The market appears to be pricing in elevated risks due to the company's loss-making status and the potential for earnings misses. Expectations may be tempered by the recent financial performance, which is below industry peers.
Management is on track with the commercial launch of lorundrostat, but financial performance remains weak. The elevated risk of an earnings miss in the near term adds uncertainty to the fundamental outlook.
The thesis hinges on the company's ability to successfully launch lorundrostat and improve its financial position. Additionally, broader sector momentum and the performance of key competitors will be important indicators.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company is ready to commercially launch lorundrostat. It also maintains sufficient cash to fund operations into 2028.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: no agreement finalized by end of 2026
Expectations to finalize an agreement with Tanabe to terminate future royalty payments.
Over the next 1 to 3 years, MLYS must navigate significant risks while capitalizing on sector trends and its product launch. Not investment advice.